Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs

Area of Science:

• Pharmacogenomics
• Drug Development
• Regulatory Science

Background:

• The 2010 US FDA-DIA Pharmacogenomics Workshop convened experts to discuss integrating pharmacogenomics (PGx) into drug labels.
• This initiative builds upon a series of workshops starting in 2002, fostering collaboration between regulatory bodies, researchers, healthcare providers, and industry.

Framework:

• The workshop focused on 'Building PGx into Labels,' addressing critical elements for developing PGx outcomes that inform drug efficacy and safety.
• Discussions centered on establishing clear guidelines for the evidentiary standards required for incorporating PGx information into product labeling.

Implementation:

• Examples from US prescribing information (e.g., panitumumab, warfarin, clopidogrel) illustrated the integration of PGx knowledge into clinical decision-making.
• Considerations for appropriate PGx placement within drug labels and strategies to encourage adoption of PGx testing recommendations by medical communities were explored.

Implications:

• Attendees highlighted the need for expanded dialogue and standardized guidelines for PGx evidence in drug labels.
• Global considerations, including European Summary of Product Characteristics, were discussed in the context of worldwide drug development and regulatory harmonization.